Loading
A phase 2 trial of Netupitant and palonosetron in Breast cancer, run by Chinese University of Hong Kong, active and no longer recruiting.
AKY15-HK-301_NEPA Study is a phase 2 interventional study registered as NCT03386617 by Chinese University of Hong Kong, with 55 participants planned, started 2018-02-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: NEPA. Conditions recorded: Breast Cancer.
Linked to the drug Netupitant and palonosetron because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Netupitant and palonosetron, Breast cancer (all types) and the tag pipeline.
Shares Netupitant and palonosetron and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.